Therapy Areas: Hereditary Disorders
Intellia Therapeutics and ReCode Therapeutics join forces for gene editing therapies in cystic fibrosis
15 February 2024 -

Clinical-stage gene editing company Intellia Therapeutics Inc (NASDAQ:NTLA) and ReCode Therapeutics, a clinical-stage genetic medicines company, announced on Thursday a strategic collaboration aimed at developing novel genomic medicines to treat cystic fibrosis (CF).

Leveraging Intellia's CRISPR-based platform and ReCode's Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery system, the collaboration targets precise correction of CF disease-causing gene mutations.

Initial efforts will focus on patients with limited or no treatment options, with potential expansion later on. Intellia will lead the design of editing strategies and provide research-grade components for the investigational therapies, while ReCode will handle preclinical and clinical development, as well as global commercialisation for certain programmes arising from the collaboration.

Intellia stands to receive development and commercial milestone payments, along with royalties, and retains the option to lead commercialisation in the US for certain programmes.

Login
Username:

Password:


Related Headlines

Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines